Mesoblast

Mesoblast Financing Cash Flow

The Net Financing Cash Flow of Mesoblast (MSB.AX) as of Nov 19, 2026 is -15.33 M USD. In the previous year, Net Financing Cash Flow was 147.34 M USD — a change of -110.40% (lower).

Financing Cash Flow

-15.33 MUSD

YoY

-110.40%

Last updated:

Net Financing Cash Flow of Mesoblast is 2026 -15.33 M USD. Net Financing Cash Flow of Mesoblast was 2025 147.34 M USD. It decreases by -110.40% lower compared to the previous year.

The Mesoblast Financing Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financing Cash Flow
Date
Financing Cash Flow
Jan 1, 2019
71.61 M USD
Jan 1, 2020
137.04 M USD
Jan 1, 2021
114.47 M USD
Jan 1, 2022
-9.87 M USD
Jan 1, 2023
74.50 M USD
Jan 1, 2024
40.25 M USD
Jan 1, 2025
147.34 M USD
Jan 1, 2026
-15.33 M USD
The Mesoblast Financing Cash Flow history
YEARFinancing Cash FlowYoY
-15.33 MUSD-110.40%
147.34 MUSD+266.03%
40.25 MUSD-45.97%
74.50 MUSD-854.83%
-9.87 MUSD-108.62%
114.47 MUSD-16.48%
137.04 MUSD+91.38%
71.61 MUSD+4.37%
68.61 MUSD+14.35%
60.01 MUSD-3.32%
62.07 MUSD+35.36%
45.85 MUSD+1,786.91%
2.43 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Mesoblast Stock analysis

What does Mesoblast do? Mesoblast Ltd is an Australian biotechnology company specializing in the development and production of novel cell-based therapies for serious diseases. The company was founded in 2004 as a spin-off of the Australian Monash University. Mesoblast's business model is based on the development of cell-based therapies using mesenchymal stem cells (MSCs). The company has specialized in researching MSCs and holds patents for their use in various medical fields. Mesoblast has developed an innovative technology platform to produce MSCs on a large scale and ensure high activity and quality of their products. Mesoblast has three different divisions covering different areas of medicine. The first division focuses on cardiovascular diseases and researches MSC-based therapies for patients with heart conditions such as heart attack or heart failure. The company has already conducted clinical trials with positive results. The second division focuses on orthopedics and spine, aiming to improve the regeneration of poorly healing bone fractures or chronic back problems. Mesoblast has also conducted clinical trials in this area with positive results. The third division focuses on immunology and inflammation, aiming to develop therapeutic applications that regulate inflammatory reactions in the body. These therapies could be used, for example, in autoimmune diseases. Mesoblast offers various products based on the use of MSCs. One of the main products is Temcell, a therapy used to treat graft-versus-host disease (GvHD). GvHD is a life-threatening complication that can occur after a stem cell transplant. Temcell aims to modulate the patient's immune system and alleviate the symptoms of GvHD. Another product of Mesoblast is Revascor, an intravenous infusion used to treat patients with severe heart failure. Revascor contains live MSCs that are intended to promote heart muscle regeneration and improve heart function. Mesoblast is an innovative company specializing in the development of cell-based therapies. The company has already achieved notable successes and is expected to continue bringing groundbreaking products to the market in the future. Mesoblast is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Mesoblast stock

Net Financing Cash Flow of Mesoblast is -15.33 M USD in 2026.

Net Financing Cash Flow of Mesoblast changed from 147.34 M USD to -15.33 M USD, representing a -110.40% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Financing Cash Flow Mesoblast since 2006 – with annual values, charts, and detailed analysis.

Financing cash flow measures cash flows from debt issuance/repayment, equity transactions, and dividend payments.

Net Financing Cash Flow's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Financing Cash Flow's Mesoblast historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Mesoblast

All Key Metrics — Mesoblast